For families and healthcare professionals
A guide for families and healthcare professionals before starting a new medication
CA II deficiency is a rare inherited condition. Clinical features vary greatly between individuals, so this guide cannot make an individual medication decision without the treating team.
CA II deficiency may be associated with osteopetrosis; renal tubular acidosis, sometimes with proximal and distal components; bicarbonate or potassium disturbances; nephrolithiasis/nephrocalcinosis in some patients; and impaired osteoclast-mediated bone resorption. Not every person has every feature. Decisions depend on the clinical pattern and current state.
These medicines deserve disclosure of CA II/RTA before prescribing because they can inhibit carbonic anhydrase, lower bicarbonate, or cause/worsen metabolic acidosis. This does not make them automatically contraindicated for every patient.
High alert · drug-label / RTA evidence
Can cause hyperchloremic non-anion-gap metabolic acidosis through renal bicarbonate loss related to carbonic anhydrase inhibition. Its label says conditions or treatments that predispose to acidosis may have additive effects, and stone risk rises through changes including increased urinary pH and reduced citrate. CA II deficiency with RTA makes its effect on bicarbonate and acid-base balance important for the prescriber to know.
High alert · drug-label / RTA evidence
Can also cause hyperchloremic non-anion-gap metabolic acidosis from renal bicarbonate loss caused by carbonic anhydrase inhibition. Predisposing conditions may be additive. It needs special review in a patient with RTA or bicarbonate disturbance.
High alert · direct CA II data + drug label
Its label lists depressed sodium/potassium and hyperchloremic acidosis among drug-specific contraindications and it can cause electrolyte imbalance, hypokalaemia, and acidosis. A historical physiological study in CA II-deficient patients showed a renal response to intravenous acetazolamide, demonstrating remaining acetazolamide-inhibitable renal activity. It does not establish routine therapeutic safety in CA II, nor does it show that one exposure inevitably causes fatal collapse.
High alert · drug-label / RTA evidence
A carbonic anhydrase inhibitor. Its label lists hyperchloremic acidosis and depressed sodium/potassium among contraindications; it can lower bicarbonate and increase urinary potassium loss.
High alert · drug-label / RTA evidence
Can cause metabolic acidosis and hypokalaemia. Its label notes greater hypokalaemia risk in conditions associated with hypokalaemia, including RTA. Unrelated drug–drug interactions should not be generalized to all CA II patients.
Dorzolamide and brinzolamide are ophthalmic carbonic anhydrase inhibitors with systemic absorption. Dorzolamide’s label includes renal considerations and possible electrolyte/acidosis effects in overdose; it is not recommended in severe renal impairment. Brinzolamide is also not recommended in severe renal impairment. Direct CA II evidence is insufficient to call these drops universally contraindicated: tell the eye clinician about CA II and RTA/kidney issues before use.
Review & monitoring · indirect additive-risk evidence
Furosemide can cause potassium and other electrolyte depletion, particularly with substantial diuresis. Some people with CA II have documented hypokalaemia with RTA. If potassium is low or unstable, the prescriber needs to know when considering a medicine that can increase potassium loss. This does not make furosemide prohibited or imply an automatic alternative.
Review & monitoring · indirect additive-risk evidence
Systemic amphotericin B has established nephrotoxicity and can cause RTA, hypokalaemia, and sodium/magnesium wasting. Existing tubular/electrolyte problems create an additive-risk concern, not a CA-II-specific contraindication.
Review & monitoring · indirect additive-risk evidence
Lithium can be associated with chronic tubulointerstitial kidney injury and distal RTA can occur. This is an additive kidney/RTA consideration rather than a CA-II-specific contraindication.
CA II osteopetrosis results from impaired osteoclast-mediated bone resorption. Bisphosphonates suppress this resorption and denosumab reduces osteoclast development/activity through RANKL, so a fracture in osteopetrosis should not automatically be treated as ordinary osteoporosis. They are not absolute CA II contraindications: antiresorptives have been used in highly specialized settings, including hypercalcaemia after HSCT in osteopetrosis. They need assessment by a bone/metabolic specialist who understands the osteopetrosis type and the specific indication.
Specialist assessment · mechanistic/specialist context
It is not accurate to say that calcium or vitamin D routinely accelerate cerebral calcification in CA II. Published cases have received calcium and/or vitamin D as individualized care. Need and dose depend on calcium, phosphate, vitamin D status, kidney function, stone/nephrocalcinosis history, and other mineral/bone issues. The concern is not calcium or vitamin D themselves, but unmonitored or unsuitable use. Do not start or stop supplements without the treating team.
Individualized supplementation · clinical context
Not appearing here does not make a medicine automatically safe; appearing here does not make it automatically forbidden. Suitability can depend on age, weight, dose, hydration, kidney/liver function, allergies, current electrolytes and medicines, and the illness being treated. This is not a medication whitelist or interaction checker.
“My child has Carbonic Anhydrase II Deficiency (CA2-related osteopetrosis with renal tubular acidosis). Please consider the medicine’s effects on acid-base balance and bicarbonate, potassium, renal tubules, stone risk, and bone.”
Bring the current medication and supplement list, including prescribed bicarbonate or citrate/potassium therapy if applicable.
Vomiting, diarrhoea, poor oral intake, dehydration, severe infection, or another acute illness can change fluid, electrolyte, and acid-base status and alter the benefit/risk assessment of a new medicine. Tell the clinician if the child is drinking poorly, vomiting, has diarrhoea, or recent results show bicarbonate or potassium disturbance. This page does not create a home electrolyte-treatment protocol.
المريض مصاب بنقص Carbonic Anhydrase II المرتبط بـCA2. قد يترافق المرض مع renal tubular acidosis واضطرابات البيكربونات والبوتاسيوم، وحصوات/تكلس كلوي، وosteopetrosis بدرجات متفاوتة.
عند وصف دواء جديد، يرجى مراعاة تأثيره على carbonic anhydrase، التوازن الحمضي-القاعدي، البيكربونات، البوتاسيوم، وظيفة الأنابيب الكلوية، خطر الحصوات، واستقلاب/ارتشاف العظم.
وجود CA II deficiency لا يجعل كل الأدوية في هذه الفئات ممنوعة تلقائيًا؛ القرار يعتمد على الحالة الحالية، الاستطباب، والمراقبة المناسبة.
This patient has CA2-related Carbonic Anhydrase II Deficiency, which may be associated with renal tubular acidosis, bicarbonate and potassium disturbances, nephrolithiasis/nephrocalcinosis, and osteopetrosis of variable severity.
Before starting a new medication, please consider its effects on carbonic anhydrase activity, acid-base balance, serum bicarbonate and potassium, renal tubular function, stone risk, and bone resorption.
CA II deficiency does not automatically contraindicate every medication in these categories; treatment decisions should be individualized according to the current clinical state, indication, and appropriate monitoring.
When clinically relevant, consider the patient's current acid-base and renal/electrolyte status rather than relying on the diagnosis alone.
Bicarbonate/total CO2, potassium, sodium, creatinine/renal function, hydration, stone/nephrocalcinosis history, current alkali/potassium therapy, and other medicines capable of acidosis or electrolyte loss may be considered by clinical context; they are not mandatory tests for every medicine.
The labels on medication cards describe the type of evidence, not a numeric “safety score.” There is no broad medication evidence base specific to CA II alone.